Literature DB >> 6571787

Efficacy and morbidity of central nervous system "prophylaxis" in childhood acute lymphoblastic leukemia: eight years' experience with cranial irradiation and intrathecal methotrexate.

A Inati, S E Sallan, J R Cassady, S Hitchcock-Bryan, L A Clavell, J A Belli, N Sollee.   

Abstract

Between 1972 and 1979, 214 children with acute lymphoblastic leukemia and no evidence of central nervous system (CNS) disease prior to CNS prophylaxis were treated with 2400 rad cranial irradiation and concurrent intrathecal methotrexate. Only nine children developed CNS leukemia; five of them in the CNS only and four concurrently in the CNS and another site. Major acute effects of CNS prophylaxis were seizures in seven patients (3%). Sixty-nine children who had a minimum follow-up of 4 yr were evaluable for late effects of therapy. Small cataracts, incomplete regrowth of hair, and learning disabilities were noted. The latter occurred in 18% of patients, an incidence similar to that encountered in a normal community of school-age children. However, the incidence of learning disabilities in patients who were under 5 yr of age at the time of diagnosis was much higher, 35%. We conclude that the combination of cranial irradiation and intrathecal methotrexate was highly efficacious. The incidence and severity of neuropsychologic abnormalities, the principal late morbidity of this treatment program, varies among reporting institutions. Prospective longitudinal studies of neuropsychologic function are necessary to better define the incidence of abnormalities. Future programs should attempt to decrease late morbidity, but must also assure equal efficacy and improve overall disease-free survival.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6571787

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Radiation-induced glioblastoma multiforme in a remitted acute lymphocytic leukemia patient.

Authors:  Daewon Joh; Bong Jin Park; Young Jin Lim
Journal:  J Korean Neurosurg Soc       Date:  2011-09-30

Review 2.  CNS prophylaxis of childhood leukemia: what are the long-term neurological, neuropsychological, and behavioral effects?

Authors:  J A Stehbens; T A Kaleita; R B Noll; W E MacLean; R T O'Brien; M J Waskerwitz; G D Hammond
Journal:  Neuropsychol Rev       Date:  1991-06       Impact factor: 7.444

3.  Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.

Authors:  Yousif Matloub; Susan Lindemulder; Paul S Gaynon; Harland Sather; Mei La; Emmett Broxson; Rochelle Yanofsky; Raymond Hutchinson; Nyla A Heerema; James Nachman; Marilyn Blake; Linda M Wells; April D Sorrell; Margaret Masterson; John F Kelleher; Linda C Stork
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

4.  Functional and structural differences in the hippocampus associated with memory deficits in adult survivors of acute lymphoblastic leukemia.

Authors:  Michelle Monje; Moriah E Thomason; Laura Rigolo; Yalin Wang; Deborah P Waber; Stephen E Sallan; Alexandra J Golby
Journal:  Pediatr Blood Cancer       Date:  2012-08-08       Impact factor: 3.167

5.  Dihydrofolate reductase-activity in brain tissue. Effect of X-irradiation.

Authors:  R Ludwig; E Frei; B Kimmig; W E Brandeis
Journal:  Blut       Date:  1987-12

6.  Vascular changes of methotrexate-related disseminated necrotizing leukoencephalopathy.

Authors:  K Suzuki; T Takemura; R Okeda; S Hatakeyama
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

7.  Combined intraommaya methotrexate, cytosine arabinoside, hydrocortisone and thio-TEPA for meningeal involvement by malignancies.

Authors:  D J Stewart; J A Maroun; H Hugenholtz; B Benoit; A Girard; M Richard; N Russell; L Huebsch; J Drouin
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.